@LiamCristiano @dangermanisreal it does reduce FSH and LH, but not that much, and ofcourse dose dependent
Commentary stating that the substance reduces follicle-stimulating hormone (FSH) and luteinizing hormone (LH) modestly, with effects that depend on dose. The post does not reference any company, product, or investable security.
Linked assets
Ticker listed: LH — included as a biological marker (luteinizing hormone) referenced in the commentary. No corporate or market tickers, ETFs, or tradable instruments are identified.
Reference to luteinizing hormone (LH) as a biological marker discussed in the commentary. The post indicates modest LH suppression that scales with dose; no corporate or market implications.
@LiamCristiano @dangermanisreal it does reduce FSH and LH, but not that much, and ofcourse dose dependent @LiamCristiano @dangermanisreal it does reduce FSH and LH, but not that much, and ofcourse dose dependent
Source proof
Source proof: Supported source proof | 1 extracted claim | 1 directional asset | 1 supporting author | headline-like title review
Primary source is a social-media style comment: “@LiamCristiano @dangermanisreal it does reduce FSH and LH, but not that much, and ofcourse dose dependent.” Related posts discuss topical testosterone/DHT effects on the HPG axis and other informal health/product remarks. None of the sources link to companies, drugs, catalysts, pricing, or investment implications.
Commentary about an unspecified substance reducing FSH and LH modestly, in a dose-dependent manner. No company, drug, catalyst, or tradable asset is identified.
Discussion about physiological effects of topical testosterone and DHT on HPG axis activity; no explicit market, company, product, or investable asset referenced.
The source only states that the user has heard “tons of strong reviews” about @JK99928789839, with no identifiable company/ticker, product, catalyst, timeframe, or tradable implication.
Non-financial social post about skincare/sun exposure increasing skin sensitivity; no market, company, or asset implications.
Post claims that for people with candida, temporarily cutting complex carbohydrates is key to getting rid of it. No mention of markets, companies, products, or investable assets.
The content is a brief product recommendation (Miyasi brand on Amazon) with no market, macro, earnings, regulatory, or industry details. It is not actionable for investment/trading purposes beyond a very general Amazon marketplace context.
The provided text is a personal question about “form and dosage” with no market, macro, sector, or company information. It is not actionable for investment research and contains no tradable signals or tickers.
Discussion of supplement/compound 9-me-bc pharmacology (half-life, MAO inhibition, potential toxic beta-carboline metabolites). No companies, products, catalysts, pricing, or market/financial implications provided.
Supporting authors
Single author/commenter referenced by handle: @LiamCristiano. Other related posts cited include handles @dangermanisreal, @JK99928789839, @Jenibee1732, @dr4cdac, @DdrHdee79355, @daddynigga22, and @NorKris20, but those are informal comments and not company spokespeople or published research authors.
Unlock full thesis monitoring
This note is informational about physiological effects only and is not investment advice. No tradable recommendation is implied beyond the stated biological observation.